Endocrinology 150 , 11741181 (2009)
Incretin-pathway research has advanced from single-receptor agonism toward multi-receptor strategies that interrogate energy balance, glucose handling, hepatic lipid flux, and satiety circuits in a coordinated fashion
A subgroup meta-analysis was conducted based on the type of GLP-1 RA used, separately for three treatment durations: 3 months, 6 months, and 12 months
Lets translate this into clinical reality Absolute risk reduction 3.7% over 3 years NNT 27 So yes this is clinically meaningful But heres the uncomfortable truth: This benefit is conditional
Helps with overall recovery and healing
Some studies suggest that GLP-1 agonists may reduce the risk of cardiovascular events, like heart attacks and strokes, which is especially beneficial for people with diabetes or metabolic syndrome